LTS Enhances Its CDMO Capabilities with Acquisition
ANDERNACH, Germany – LTS LOHMANN Therapie-Systeme AG ("LTS"), a prominent player in the pharmaceutical technology sector, has announced an exciting acquisition. The company has joined hands with Renaissance Lakewood, LLC ("Renaissance"), a contract development and manufacturing organization (CDMO) based in the United States, known for its specialization in nasal sprays and sterile dosage forms.
Strategic Expansion of Operational Network
This acquisition signifies a pivotal moment for LTS as Renaissance's facilities merge with LTS’s extensive global operations network. LTS already boasts several facilities in Andernach, Germany, West Caldwell, NJ, St. Paul, MN, and Netanya, Israel, making this move a significant enhancement to their capacity.
Enhancing Drug Delivery Expertise
The joining of forces with Renaissance strengthens LTS's foothold in the CDMO landscape by integrating Renaissance’s advanced manufacturing capabilities, a highly skilled workforce comprising around 500 employees, and their rich expertise in the development of drug delivery solutions. LTS aims to leverage this partnership to provide a more diverse array of drug delivery systems, focusing on innovation and quality.
Renaissance’s Historical Significance
Established in 1979 and currently under the ownership of RoundTable Healthcare Partners, Renaissance has built a reputation for excellence. Operating from multiple manufacturing suites, the company excels in producing unit-dose and multi-dose nasal sprays, as well as filling parenteral vials. Their robust laboratories also support essential R&D formulation work, establishing them as a critical partner from development stages through launch.
Commitment to Innovation
Renaissance’s acquisition aligns perfectly with LTS’s sustained commitment to pioneer innovation within the drug delivery space. As LTS integrates Renaissance's advanced capabilities, it is strategically positioned to cater to a wider spectrum of pharmaceutical and biotech partners, enhancing the value offered in therapeutics.
Voices from Leadership
Bas van Buijtenen, the CEO of LTS, spoke enthusiastically about the acquisition: "We are incredibly thrilled to welcome Renaissance Lakewood into the LTS family. This integration is not just a growth moment—it marks a monumental step in enhancing our CDMO capabilities, allowing us to thrive as a global leader in innovative drug delivery solutions. The exceptional expertise of Renaissance in nasal sprays perfectly complements our existing portfolio, helping us to serve our partners and patients with increased effectiveness. We eagerly anticipate this collaboration as we pursue greater innovation and high-quality solutions across various therapeutic areas."
Looking to the Future
Serge Maltais, the President & CEO of Renaissance, echoed similar sentiments, noting the strong foundation built at Renaissance due to the dedication of its employees. "Being part of the LTS family amplifies our capabilities, enabling us to better meet the intricate needs of our clients and deliver enhanced value to the industry. We are eager to embark on this new journey together, striving for shared success."
Path Ahead
The milestone acquisition is anticipated to finalize by the end of November 2025, pending the necessary regulatory approvals. This development reinforces LTS’s long-term vision of expanding its presence and impact in the pharmaceutical technology market.
About LTS Lohmann Therapie-Systeme AG
LTS is driven by a commitment to quality, creativity, and delivery in the pharmaceutical industry. Renowned as a trusted technology partner, LTS develops innovative drug delivery systems such as Transdermal Patches and Oral Thin Films, as well as wearable devices. Their commercial portfolio includes over 20 marketed products and an extensive pipeline of over 40 projects aimed at addressing various health challenges. LTS is focused on refining its technologies and pioneering new drug delivery innovations to maintain its leading industry position.
About Renaissance Lakewood, LLC
Renaissance stands out as a U.S.-based CDMO for pharmaceutical and biotech industries. With decades of experience in nasal sprays and sterile dosage forms, Renaissance is recognized for its commitment to exceptional service throughout the development and commercial stages. Their rich history of innovation positions them as a valuable partner in the medical community.
Frequently Asked Questions
1. What does the acquisition of Renaissance Lakewood mean for LTS?
The acquisition allows LTS to expand its CDMO capabilities, enhancing its range of drug delivery solutions.
2. When is the acquisition expected to close?
The acquisition is anticipated to close by the end of November 2025, subject to regulatory approval.
3. How will this acquisition benefit pharmaceutical partners?
It will enable LTS to offer a broader range of therapeutic solutions and improve service quality.
4. What expertise does Renaissance bring to LTS?
Renaissance contributes deep knowledge in nasal sprays and sterile dosage forms, along with advanced manufacturing capabilities.
5. What is LTS’s commitment to innovation?
LTS is committed to continuously refining and innovating drug delivery technologies to address diverse medical needs.
